Myriad Genetics Q1 Product Revenues Increase 3 Percent
The company reported revenues of $164.9 million, all of which came from its molecular testing business, beating analysts' consensus expectation.
Source: 360dx.com
Page 7 - Bracanalysis Cdx News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Bracanalysis Cdx. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Bracanalysis Cdx Today - Breaking & Trending Today
FDA Approves First PARP Inhibitor for Early BRCA+ Breast Cancer
Overall survival results showing a 32% reduction in mortality with olaparib vs placebo will be presented at an upcoming EMSO virtual plenary session.
Source: medscape.com
FDA OKs PARP Inhibitor as Adjuvant Therapy in Early Breast Cancer
Olaparib (Lynparza) approved for high-risk patients with germline <em>BRCA</em> mutations
Source: medpagetoday.com
Myriad Genetics Receives FDA Approval of BRACAnalysis CDx as a Companion Diagnostic for Lynparza in Early Breast Cancer
12.03.2022 - BRACAnalysis CDx is now the only germline test approved by FDA as a companion diagnostic for treatment of HER2 negative high-risk early-stage breast cancerSALT LAKE CITY, March 11, 2022 (GLOBE NEWSWIRE) - Myriad Genetics, Inc., (NASDAQ: MYGN), a ... Seite 1
Source: wallstreet-online.de
Myriad Genetics Receives FDA Approval of BRACAnalysis® CDx as a Companion Diagnostic for Lynparza® in Early Breast Cancer
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Source: apnews.com